Import from '@/components/mdx'

Bonafide BBB and Consumer Complaint Trends: An Independent Review

Is Bonafide a Legitimate Company?

Bonafide is a real, operating company with products you can hold in your hand and clinical references you can read. It is not a scam in the sense of taking money and disappearing. The brand was founded in 2017 and markets products directly to women experiencing perimenopause and post-menopause, positioning itself as science-backed and physician-formulated. It holds an active BBB accreditation and an A rating, which reflects responsiveness to complaints rather than clinical proof of efficacy.

The more useful question is not whether Bonafide is "legit" but whether its products do what they claim, whether the business practices are transparent, and whether the complaint volume reveals patterns women should consider. Each of those deserves a direct answer.

BBB Accreditation: What It Actually Means

BBB accreditation means a business has applied, paid a membership fee, and agreed to respond to complaints. A high letter grade reflects complaint resolution rates and business transparency, not product safety or clinical effectiveness. The BBB's own methodology weights factors including time in business, complaint history, and whether the business responds. A supplement company can earn an A and still sell a product with weak clinical evidence.

Bonafide's A rating is genuinely better than many supplement brands. Some direct competitors in the menopause space carry B or lower ratings, or are not accredited at all. That is a meaningful signal about customer service responsiveness, though it says nothing about whether pollen extract will reduce your hot flashes.

FDA Status and Regulatory Oversight

Bonafide's products are sold as dietary supplements, which means they are regulated under DSHEA (the Dietary Supplement Health and Education Act of 1994). Under DSHEA, companies do not need to prove safety or efficacy before selling a product. The FDA can act after a product is on the market if harm is reported, but pre-market approval is not required.

This is not specific to Bonafide. Every non-hormonal menopause supplement on the market operates under the same rules. What distinguishes Bonafide is that it cites specific clinical studies for some products, particularly Relizen, which allows you to evaluate those references directly rather than relying on marketing language.

The FDA has not issued any warning letters to Bonafide as of January 2025. You can verify that in the FDA warning letter database.

What the BBB Complaint Data Actually Shows

The BBB complaint file for Bonafide, reviewed in January 2025, shows a pattern common to subscription-based D2C wellness companies. The complaints are real and worth understanding, because they describe what can go wrong even when a company is technically operating within its stated terms.

The Subscription Billing Problem

The most frequent complaint category involves subscription billing. Women describe signing up for a trial or a discounted first shipment, not fully registering that they were enrolling in an auto-renewing plan, and then being charged for subsequent orders they did not expect.

This is not unique to Bonafide. The FTC has pursued multiple supplement and wellness companies over negative-option marketing practices, which is the technical term for plans that continue unless you actively cancel. Bonafide's terms do disclose the subscription model, but the complaints suggest the disclosure is not always prominent enough at the point of purchase for every customer.

If you are considering Bonafide, read the checkout page carefully. Look for language about auto-renewal before completing purchase, and note the cancellation process before you need it.

Return Policy Friction

A secondary complaint theme involves difficulty getting refunds, particularly for opened products. Bonafide's stated return policy allows returns within a defined window, but several complainants describe customer service delays, requirements to return opened bottles, and partial rather than full refunds. The BBB complaint file shows that the company generally does respond and often resolves these disputes, which is why the rating remains high, but the process is not always smooth.

Efficacy Complaints

Some complaints are not about business practices at all. They express disappointment that a product did not relieve hot flashes, sleep disruption, or other menopause symptoms. These are worth reading not as evidence of fraud but as a reminder that dietary supplements do not work for everyone. The clinical evidence for pollen extract, discussed below, shows statistically significant symptom reduction in trials but not universal response.

The Clinical Evidence Behind Bonafide's Products

This is where Bonafide differentiates itself from most supplement brands, and where honest evaluation matters most. Rather than citing generic "studies show" marketing, Bonafide points to specific published research. That research deserves direct scrutiny.

Relizen: The Pollen Extract Evidence

Relizen contains a standardized purified pollen extract called Sérélys, derived from Swedish flower pollen and pistils. The most-cited study supporting it is a randomized, double-blind, placebo-controlled trial published in Gynecological Endocrinology. In that trial, 64 post-menopausal women received the pollen extract or placebo for three months, and the treatment group reported a statistically significant reduction in hot flash frequency compared to placebo. A 2015 review in Climacteric examined multiple pollen extract trials and found consistent signals for hot flash reduction, though the authors noted the trials were small and industry-linked.

The honest summary: the evidence is better than zero and better than most comparable supplements, but it does not approach the quality of evidence behind FDA-approved menopause therapies. The Menopause Society (formerly NAMS) position on non-hormonal therapies notes that most botanical and supplement options have limited, inconsistent, or low-quality evidence. That does not mean they cannot work for an individual woman. It means the population-level confidence is low.

Ristela and Sexual Health Products

Bonafide markets Ristela for sexual function, containing French maritime pine bark extract (Pycnogenol) and L-arginine. A published trial in the Journal of Sexual Medicine examined a similar formulation and found improvement in sexual function scores, though again in a small sample. The evidence base for women's sexual health supplements is thin across the board, in part because female sexual dysfunction has been chronically under-studied in clinical trials.

Research on female sexual dysfunction has historically lagged behind comparable male research, which means the evidence gap is not Bonafide's fault but it is real. Be skeptical of strong efficacy claims, and discuss options with a clinician who specializes in women's sexual health before choosing a supplement over evaluated therapies.

Ovaboost and Fertility Products

Bonafide sells Ovaboost, targeted at women trying to conceive, containing myo-inositol, folate, melatonin, CoQ10, and other ingredients associated with egg quality support. Myo-inositol has reasonable evidence in women with PCOS for improving insulin sensitivity and ovulation. A 2012 trial in Gynecological Endocrinology found that myo-inositol supplementation improved oocyte quality markers in women undergoing IVF. However, translating IVF-context data to general fertility improvement for all women is an extrapolation, and this product should be discussed with a reproductive endocrinologist before use.

Life-Stage Guide: Who This Brand Is and Is Not For

Bonafide's product line spans several women's life stages, and the relevant evidence and cautions differ by stage.

Perimenopause (Typically Ages 40-51)

This is Bonafide's core market. Women in perimenopause experience irregular cycles, hot flashes, sleep disruption, and mood changes driven by fluctuating estrogen. For women who prefer to avoid or are not candidates for menopausal hormone therapy (MHT), non-hormonal supplements represent a real option worth considering. The evidence for Relizen is modest but non-trivial, and the safety profile appears acceptable for most healthy perimenopausal women.

Perimenopause is also when hormonal contraception decisions intersect. Women using hormonal contraceptives during perimenopause for cycle regulation or contraception should be aware that supplements can interact with medications, though pollen extract has no documented interactions with oral contraceptives in the published literature as of this review.

Post-Menopause

Post-menopausal women are the population in whom most of the pollen extract trials were conducted. The evidence, such as it is, applies most directly to this group.

Trying to Conceive

Ovaboost is positioned for this stage. Given the presence of melatonin and high-dose micronutrients, confirm with your reproductive endocrinologist or OB-GYN before starting any supplement if you are actively trying to conceive. ACOG recommends that women planning pregnancy ensure adequate folic acid intake (400-800 mcg daily) from reliable sources before conception, and Ovaboost does contain folate, though supplement-delivered folate is not a substitute for medical prenatal care.

Reproductive Years (Not Trying to Conceive)

For women in reproductive years who are not perimenopausal, most Bonafide products are not relevant. The menopause-targeted products are designed for estrogen-deficient states. Using them during regular ovulatory cycles has no documented benefit and has not been studied.

Pregnancy and Lactation Safety

This section applies to all Bonafide products and is not qualified by which product you are considering.

Bonafide's menopause-focused supplements, including Relizen, have not been studied in pregnant women. Pollen extract safety in pregnancy is unknown. The general principle for dietary supplements is that absence of evidence of harm is not evidence of safety during pregnancy, because pregnant women are routinely excluded from supplement trials.

Do not use Relizen, Ristela, or any Bonafide menopause supplement during pregnancy. This is the position you should take until there is specific human data showing safety, which currently does not exist.

For Ovaboost, the situation is slightly different. Some of its ingredients, particularly folate and CoQ10, are used in fertility and early pregnancy contexts, but the full formulation, including melatonin at supplemental doses, has not been studied in pregnant women. The FDA's guidance on dietary supplements during pregnancy advises consulting a healthcare provider before using any supplement while pregnant or breastfeeding.

Lactation data for any Bonafide product is absent. Transfer of pollen extract constituents into breast milk is unknown. The standard clinical guidance applies: when data is missing, the precautionary default is avoidance during breastfeeding unless a clinician with access to your full clinical picture advises otherwise.

If you need contraception and are using Bonafide products, no Bonafide supplement is a contraceptive. None will protect against pregnancy. Women who need reliable contraception should use a method evaluated for that purpose.

PCOS, Endometriosis, and Other Conditions

Bonafide's Ovaboost line has the clearest application in PCOS, given the myo-inositol content. A meta-analysis in Reproductive BioMedicine Online found that myo-inositol improved menstrual regularity and reduced androgen levels in women with PCOS, though the authors noted heterogeneity across trials.

For endometriosis, fibroids, or estrogen-sensitive conditions, the menopause-focused products warrant caution. Pollen extract is described as non-estrogenic in mechanistic studies, which is part of its appeal for women who cannot use estrogen. The clinical trial evidence supports that it does not stimulate estrogen-responsive tissue in the same way phytoestrogens do. Still, women with a personal history of estrogen-receptor-positive breast cancer or active endometriosis should discuss any supplement with their oncologist or gynecologist before use.

Female pattern hair loss (androgenic alopecia) and hormonal acne, both common in PCOS, are not directly addressed by Bonafide's current product line.

How Bonafide Compares to Evaluated Alternatives

A fair consumer review should name what else exists, so you can compare.

For hot flash management in women who cannot or prefer not to use MHT, the options with the strongest evidence include:

• Cognitive behavioral therapy (CBT): The MENOS 1 trial showed CBT reduced problem ratings of hot flashes by 50% in breast cancer survivors, a population that cannot use estrogen.
• Fezolinetant (Veozah): An FDA-approved non-hormonal prescription drug (NK3 receptor antagonist) for moderate to severe vasomotor symptoms. Approved by the FDA in May 2023, it has the strongest non-hormonal clinical evidence available.
• SSNRIs and SSRIs at low dose: Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI for vasomotor symptoms, with published efficacy data from a multi-site randomized trial.

Bonafide occupies a real niche for women who want to try something before prescription medication, or who are not candidates for any of the above. That is a defensible position. The complaint is when marketing language implies equivalence to clinical interventions that have substantially more evidence.

What to Check Before You Buy

Before placing a Bonafide order, do four specific things.

First, read the checkout page for auto-renewal language before entering payment information. Note the cancellation method, whether that is online, by phone, or email, and write it down.

Second, check whether a one-time purchase option exists. Several Bonafide products can be purchased without a subscription at a higher per-unit price. For a first trial, that may be worth the cost difference to avoid cancellation friction.

Third, look up the specific product's clinical references on PubMed directly. Bonafide's website links to studies, but reading the abstract yourself tells you the sample size, the funder, and whether the population studied resembles you.

Fourth, tell your clinician you are considering the product. Supplement use should be documented in your medical record so that interactions can be screened and so that if symptoms worsen or do not improve, the conversation about next steps is grounded in what you have already tried.

The Evidence Gap: A Candid Note

Women have been systematically under-represented in clinical trials for decades. A 2020 analysis in the Journal of the American Heart Association found that women represented only 38% of cardiovascular trial participants despite bearing a comparable disease burden. The menopause supplement space is not exempt from this pattern. Most pollen extract trials enrolled fewer than 100 women, were conducted in Europe, and had industry involvement. The data we have is worth knowing but it is not sufficient to draw firm conclusions about which individual woman will respond.

When Bonafide says a product is "clinically studied," that is technically accurate for some products. What it does not mean is that the evidence meets the bar required for FDA drug approval or that large, independent replication trials exist. Being honest about this distinction is not an argument against trying the product. It is an argument for calibrating expectations and maintaining a relationship with a clinician who can offer alternatives if the supplement does not help.